New CoreValve Evolut 23mm Technology for Treatment of Degenerated Bioprosthesis

Dennis Zavalloni; Mauro De Benedictis; Paolo Pagnotta; Innocenzo Scrocca; Patrizia Presbitero

doi:10.1016/j.hlc.2013.08.002

New CoreValve Evolut 23mm Technology for Treatment of Degenerated Bioprosthesis

Dennis Zavalloni, Mauro De Benedictis, Paolo Pagnotta, Innocenzo Scrocca, Patrizia Presbitero

Istituto Clinico Humanitas

Research output: Contribution to journal › Article

Abstract

The treatment of degenerated surgical bio-prosthetic heart valves (BHV) has been reported as a novel indication for TAVI. The intervention may be complicated by high residual transvalvular gradients and coronary ostia obstruction, especially in small size BHV. We report two cases of BHVs treated with the new CoreValve Evolut 23. mm highlighting the importance of fluoroscopic guidance, based on BHV markers, in achieving a correct TAVI implantation. The small dimensions of the new CoreValve Evolut 23 allowed us to obtain low residual gradients even in this particular subset of degenerated BHV.

Original language	English
Pages (from-to)	183-185
Number of pages	3
Journal	Heart Lung and Circulation
Volume	23
Issue number	2
DOIs	https://doi.org/10.1016/j.hlc.2013.08.002
Publication status	Published - Feb 2014

Keywords

Aortic stenosis
Aortic valve replacement
Bioprosthesis degeneration
Interventional cardiology
TAVI

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.hlc.2013.08.002

Fingerprint Dive into the research topics of 'New CoreValve Evolut 23mm Technology for Treatment of Degenerated Bioprosthesis'. Together they form a unique fingerprint.

Cite this

Zavalloni, D., De Benedictis, M., Pagnotta, P., Scrocca, I., & Presbitero, P. (2014). New CoreValve Evolut 23mm Technology for Treatment of Degenerated Bioprosthesis. Heart Lung and Circulation, 23(2), 183-185. https://doi.org/10.1016/j.hlc.2013.08.002

@article{0ac5a8f9a1ee451eb55c9396c609e80c,

title = "New CoreValve Evolut 23mm Technology for Treatment of Degenerated Bioprosthesis",

abstract = "The treatment of degenerated surgical bio-prosthetic heart valves (BHV) has been reported as a novel indication for TAVI. The intervention may be complicated by high residual transvalvular gradients and coronary ostia obstruction, especially in small size BHV. We report two cases of BHVs treated with the new CoreValve Evolut 23. mm highlighting the importance of fluoroscopic guidance, based on BHV markers, in achieving a correct TAVI implantation. The small dimensions of the new CoreValve Evolut 23 allowed us to obtain low residual gradients even in this particular subset of degenerated BHV.",

keywords = "Aortic stenosis, Aortic valve replacement, Bioprosthesis degeneration, Interventional cardiology, TAVI",

author = "Dennis Zavalloni and {De Benedictis}, Mauro and Paolo Pagnotta and Innocenzo Scrocca and Patrizia Presbitero",

year = "2014",

month = feb,

doi = "10.1016/j.hlc.2013.08.002",

language = "English",

volume = "23",

pages = "183--185",

journal = "Heart Lung and Circulation",

issn = "1443-9506",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - New CoreValve Evolut 23mm Technology for Treatment of Degenerated Bioprosthesis

AU - Zavalloni, Dennis

AU - De Benedictis, Mauro

AU - Pagnotta, Paolo

AU - Scrocca, Innocenzo

AU - Presbitero, Patrizia

PY - 2014/2

Y1 - 2014/2

N2 - The treatment of degenerated surgical bio-prosthetic heart valves (BHV) has been reported as a novel indication for TAVI. The intervention may be complicated by high residual transvalvular gradients and coronary ostia obstruction, especially in small size BHV. We report two cases of BHVs treated with the new CoreValve Evolut 23. mm highlighting the importance of fluoroscopic guidance, based on BHV markers, in achieving a correct TAVI implantation. The small dimensions of the new CoreValve Evolut 23 allowed us to obtain low residual gradients even in this particular subset of degenerated BHV.

AB - The treatment of degenerated surgical bio-prosthetic heart valves (BHV) has been reported as a novel indication for TAVI. The intervention may be complicated by high residual transvalvular gradients and coronary ostia obstruction, especially in small size BHV. We report two cases of BHVs treated with the new CoreValve Evolut 23. mm highlighting the importance of fluoroscopic guidance, based on BHV markers, in achieving a correct TAVI implantation. The small dimensions of the new CoreValve Evolut 23 allowed us to obtain low residual gradients even in this particular subset of degenerated BHV.

KW - Aortic stenosis

KW - Aortic valve replacement

KW - Bioprosthesis degeneration

KW - Interventional cardiology

KW - TAVI

UR - http://www.scopus.com/inward/record.url?scp=84894285763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894285763&partnerID=8YFLogxK

U2 - 10.1016/j.hlc.2013.08.002

DO - 10.1016/j.hlc.2013.08.002

M3 - Article

C2 - 24021234

AN - SCOPUS:84894285763

VL - 23

SP - 183

EP - 185

JO - Heart Lung and Circulation

JF - Heart Lung and Circulation

SN - 1443-9506

IS - 2

ER -